Urinary Bladder Neoplasms Clinical Trial
— STERPROSERVerified date | November 2016 |
Source | Hopital Foch |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients followed in the Foch Hospital Urology Department (Suresnes): Patients justifying a
prostatectomy.
- Patients justifying prostatectomy together with the bladder (radical cystectomy for
bladder cancer).
- Patients with benign prostate hyperplasia who justified a prostatectomy. Compare serum
sexual steroid concentrations and intra-tissue on healthy prostates and prostate
adenoma, assess concentrations intra-tissue sex steroids on cancer metastasis prostate
specific blood sample under study (30mL) will be performed preoperatively in Patients
followed in Foch Hospital Urology Department (Suresnes), and a Removal of a fragment of
prostate tissue or metastasis will be analyze.
Aim is to compare serum concentrations of sexual steroids and intra-tissue on healthy
prostates and prostate adenomas compared to concentrations measured in patients operated for
prostate cancer.
Status | Completed |
Enrollment | 107 |
Est. completion date | November 12, 2016 |
Est. primary completion date | November 12, 2016 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Men aged over 18 years - Surgical indication justifying protatique prostatectomy, or complete prostatocystectomie, or removal of a metastasis of prostate cancer. - Patients affiliated to a social security scheme or benefiting from such a regime. - Patients who have given their consent to participate in writing Exclusion Criteria: - Patient received local therapy or hormonal treatment (LHRH analogue, therapy blocking androgen receptors) before surgery. - Treatment reductase inhibitors 5ARI ongoing or stopped for less than 3 months before the intervention. - Patient included in another clinical trial inconsistent with the conduct of this research. - Patient receiving treatment that could interfere with hormone levels (Prednisone, Ketoconazole, Abiraterone, Finasteride, Dutasteride). |
Country | Name | City | State |
---|---|---|---|
France | Hopital Foch | Suresnes |
Lead Sponsor | Collaborator |
---|---|
Hopital Foch |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Serum concentrations of sexual steroids and intra-tissue on healthy prostates | A bio-informatical analysis will be performed to compare steroids concentrations profiles in both arms. | 30 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02612194 -
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02805608 -
uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02534623 -
Postoperative Quality of Recovery After Transurethral Resection of the Bladder
|
N/A | |
Recruiting |
NCT02228473 -
Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort
|
N/A | |
Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
Terminated |
NCT02560038 -
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02252445 -
Propofol and Sevoflurane for Catheter-Related Bladder Discomfort
|
N/A | |
Not yet recruiting |
NCT02760953 -
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
|
N/A | |
Terminated |
NCT04430036 -
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
|
Phase 2 | |
Active, not recruiting |
NCT06289283 -
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
|
||
Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03661320 -
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
|
Phase 3 | |
Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Completed |
NCT03404791 -
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
|
Phase 1 | |
Terminated |
NCT01479348 -
Imaging Study for FdCyd and THU Cancer Treatment
|
Early Phase 1 | |
Recruiting |
NCT05742867 -
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
|
||
Recruiting |
NCT03973671 -
Prospective Sample Collection for Cancer of Bladder
|